If you have been reading about copper chelation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-30. Numbers and descriptions here follow the published literature rather than marketing material.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
| Property | Value | Notes |
|---|---|---|
| Long-term storage | -20 °C | Dry powder, sealed and protected from light |
| Working storage | 2 to 8 °C | Short-term holding; avoid repeated warming cycles |
| Purity assay | Reversed-phase HPLC with UV detection | Detection commonly near 214 nm |
| Copper assay | ICP-OES or atomic absorption | Confirms metal content and the metal-to-peptide ratio |
| Visible absorption | Roughly 520 to 600 nm | Rapid indicator of complex integrity |
Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
==== Functional struts ==== The porous-framework material [Cu3(btc)2(H2O)3], also known as HKUST-1, contains large cavities having windows of diameter ~6 Å. The coordinated water molecules are easily removed, leaving open Cu(II) sites. Kaskel and co-workers showed that these Lewis acid sites could catalyze the cyanosilylation of benzaldehyde or acetone. The anhydrous version of HKUST-1 is an acid catalyst. Compared to Brønsted vs. Lewis acid-catalyzed pathways, the product selectivity are distinctive for three reactions: isomerization of α-pinene oxide, cyclization of citronellal, and rearrangement of α-bromoacetals, indicating that indeed [Cu3(btc)2] functions primarily as a Lewis acid catalyst. The product selectivity and yield of catalytic reactions (e.g. cyclopropanation) have also been shown to be impacted by defective sites, such as Cu(I) or incompletely deprotonated carboxylic acid moities of the linkers. MIL-101, a large-cavity MOF having the formula [Cr3F(H2O)2O(BDC)3], is a cyanosilylation catalyst. The coordinated water molecules in MIL-101 are easily removed to expose Cr(III) sites. As one might expect, given the greater Lewis acidity of Cr(III) vs. Cu(II), MIL-101 is much more active than HKUST-1 as a catalyst for the cyanosilylation of aldehydes. Additionally, the Kaskel group observed that the catalytic sites of MIL-101, in contrast to those of HKUST-1, are immune to unwanted reduction by benzaldehyde.
=== Grand Lodge of Pennsylvania === Between 1818 and 1822, the Grand Lodge of Pennsylvania chartered three more Lodges in Havana; Las Delicias de la Habana No. 157 on March 2, 1818, La Recompensa de las Virtudes No. 161 on May 9, 1818, La Fidelidad Habanera No. 167 on September 16, 1819, and in Regla, another Lodge named La Union de RegIa No. 166 on April 5, 1819, but all of their charters were revoked by the end of 1822. The Grand Lodge of Pennsylvania chartered two other Lodges at Santiago de Cuba; on November 8, 1820, La Benevolencia No. 175, and on April 1, 1822, The True Philanthropy No. 181. However, these also had their charters revoked in 1826.
== History == The company was listed on the Australian Stock Exchange in 1987 as Sonic Technology Australia Ltd. Which took the pathology practice of Douglass Laboratories. In 1991, Douglass Laboratories opened a pathology branch in Adelaide, South Australia. In 1993, Colin Goldschmidt was appointed Managing Director for the group of laboratories. In 1997, Barratt Smith Moran Pathology changed its name to Capital Pathology. Sonic Healthcare acquired Lifescreen Australia. In 2000, Sonic Healthcare established its Core Values and introduced new management structures. In 2004, The Doctors Laboratory formed a partnership with the National Health Service's University College of London Hospital. In 2009, the company established the German Sonic Executive Committee to coordinate its German operations. In the US, Sonic Healthcare acquired Axiom Laboratories (Tampa, Florida) merging it with The Cognoscienti Health Institute, Piedmont Medical Laboratory (Winchester, Virginia), and East Side Clinical Laboratory (Rhode Island).
Brain natriuretic peptide (BNP), also known as B-type natriuretic peptide, is a peptide hormone secreted by cardiomyocytes in the heart ventricles in response to stretching caused by increased ventricular blood volume. BNP is one of the three natriuretic peptides, in addition to atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). BNP was first discovered in porcine brain tissue in 1988, which led to its initial naming as "brain natriuretic peptide", although subsequent research revealed that BNP is primarily produced and secreted by the ventricular myocardium (heart muscle) in response to increased ventricular blood volume and stretching. To reflect its true source, BNP is now often referred to as "B-type natriuretic peptide" while retaining the same acronym. The 32-amino acid polypeptide BNP-32 is secreted attached to a 76–amino acid N-terminal fragment in the prohormone called NT-proBNP (BNPT), which is biologically inactive. Once released, BNP binds to and activates the atrial natriuretic factor receptor NPRA, and to a lesser extent NPRB, in a fashion similar to atrial natriuretic peptide (ANP) but with 10-fold lower affinity. The biological half-life of BNP, however, is twice as long as that of ANP, and that of NT-proBNP is even longer, making these peptides better targets than ANP for diagnostic blood testing. The physiologic actions of BNP are similar to those of ANP and include decrease in systemic vascular resistance and central venous pressure as well as an increase in natriuresis.
Sources: en.wikipedia.org
=== IBP Golden Pillar of Law Award === Duterte was conferred the Golden Pillar of Law Award on September 15, 2025, from the Davao City chapter of the Integrated Bar of the Philippines (IBP). Human rights lawyers and activists urged the IBP to revoke the award viewing that his role in the war on drugs contradicts with the spirit of the recognition. The national office of the IBP maintained Duterte's presumed innocence as it "do not confer guilt or grace beyond the reach of law" but nevertheless pledge to review rules concerning the award. IBP Davao insist that Duterte satisfy the criteria for the award based on professional longevity and standing status and that the Golden Pillar award does not "serve as an endorsement of political acts or personal ideologies".
Obesity in Brazil is a major public health challenge and one of the leading risk factors for non-communicable diseases in the country. Brazil is the largest country in South America and the fifth most populous in the world, with approximately 215 million inhabitants. Since the early 21st century, Brazil has experienced a substantial increase in obesity and overweight prevalence among adults, reflecting changes in dietary patterns, physical activity levels, urbanisation, and socioeconomic conditions. According to data from the Brazilian Ministry of Health's Vigilância de Fatores de Risco e Proteção para Doenças Crônicas por Inquérito Telefônico (transl. Surveillance of Risk and Protective Factors for Chronic Diseases via Telephone Survey) (Vigitel), obesity prevalence among adults living in the 26 Brazilian state capitals and the Federal District more than doubled between 2006 and 2024.
=== Psychiatry === Stress suppresses TSH, and alterations in thyroid hormone levels may arise in psychiatric illness. In major depressive disorder, an NTIS-like phenotype may be observed, with reduced T3 and increased rT3. T4 may be elevated, and TSH is usually normal, although TSH's normal circadian rhythm may be disrupted. Bipolar 1 and PTSD can exemplify an anti-NTIS phenotype, with upregulation of the HPT axis and increased T3. This may also occur during acute schizophrenic episodes.
=== 70S scanning model === When translating a polycistronic mRNA, a 70S ribosome ends translation at a stop codon. It is now shown that instead of immediately splitting into its two halves, the ribosome can "scan" forward until it hits another Shine–Dalgarno sequence and the downstream initiation codon, initiating another translation with the help of IF2 and IF3. This mode is thought to be important for the translation of genes that are clustered in poly-cistronic operons, where the canonical binding mode can be disruptive due to small distances between neighboring genes on the same mRNA molecule.
== Background == Dr. Thomas Aoki, former Head of Metabolism Research at the Joslin Diabetes Center in Boston, Massachusetts, and a former professor of medicine at the University of California, Davis, led the field as a pioneer of using pulsatile insulin in the treatment of diabetes. Aoki's work focused on the role of liver dysfunction in diabetic metabolism. He theorized that end organ damage in diabetes is caused by abnormal hepatic glucose metabolism, inadequate insulin delivery, and insulin resistance. He called his approach Metabolic Activation Therapy (MAT), which consisted of an ever-increasing baseline of insulin using Respiratory Quotient to determine the efficiency of treatment (US Patent 4,826,810).
Sources: en.wikipedia.org
Dry powder is best kept cold, dark and sealed, typically at -20 °C for long-term storage or 2 to 8 °C for material in regular use. Vials should be warmed to room temperature before opening to prevent moisture condensing on the contents. Aqueous stock solutions degrade faster and are usually prepared fresh.
The colour comes from electronic transitions between the copper ion and the surrounding peptide nitrogen atoms. The resulting absorption sits in the visible region, giving the solid and its solutions a blue to violet appearance. Loss of colour can indicate that the copper has dissociated from the peptide.
Chromatography establishes the identity and purity of the peptide, while elemental analysis establishes the copper content. The two results should agree with a one-to-one ratio. Visible spectroscopy adds a quick check that the complex itself is intact.
It is not approved as a pharmaceutical in major markets and is used mainly as a cosmetic ingredient and a laboratory reagent. Regulatory status varies by country and by the product category in which it appears. Claims about therapeutic effects should be treated separately from permitted cosmetic labeling.